Biomanufacturing Media

  1. Oligonucleotide Opportunities In DMD With PepGen's James McArthur, Ph.D. 7/24/2022

    Duchenne muscular dystrophy affects an estimated one in 3,500 male births worldwide.  Approved treatments haven't demonstrated strong clinical outcomes, but James McArthur, Ph.D. and his team at PepGen are seeking to change that with a pipeline of disease-modifying peptide-conjugated oligo candidates derived from the company's EDO platform. 

  2. Keys To Successful mRNA Manufacturing 4/26/2022

    How can PCR-based technology accelerate mRNA development and manufacturing and design principles/critical parameters to enable the rapid development of lipids for RNA formulation?

  3. Supporting The Global Biopharma Industry With Single-Use Capacity Expansion 4/22/2022

    Explore Cytiva’s brand new single-use production facility in Wales, UK. This facility forms part of Cytiva’s >$1.5 billion investment in increased capacity to support the growing needs of the biopharmaceutical industry and to increase regional supply.

  4. The NanoAssemblr® Spark™ Robust Low Volume RNA-Lipid Nanoparticle Formulation 4/14/2022

    Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr®️ Spark™ instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.

  5. Translation Of RNA Nanomedicines From Design To Clinical 4/14/2022

    mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.

  6. mRNA LNP Scale Up For GMP Vaccine Production 4/14/2022

    Explore an overview of the development and scale-up activities needed to develop high quality lipid nanoparticles and progress this saRNA vaccine to the clinic.

  7. Democratizing RNA Nanotherapeutics 4/14/2022

    This webinar is presented by Dr. John P. Cooke, Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute, Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart and Vascular Center.

  8. Polysarcosine-Functionalized LNPs For Therapeutic mRNA Delivery 4/14/2022

    Discover how polysarcosine-functionalized lipid nanoparticles are transforming mRNA delivery. Join Dr. Heinrich Haas of BioNTech as he unveils innovative research and its implications for therapeutic breakthroughs.

  9. RNA Vaccine Development To Phase I 4/14/2022

    Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.

  10. DNA Vaccine Development In A Global Pandemic: A Personal Account 4/14/2022

    Dr. Gerrit Borchard, University of Geneva, presents a personal account of DNA vaccine development in a global pandemic.